Decisional Needs and Patient Treatment Preferences for Heart Failure Medications: A Scoping Review

[1]  Lawrence A Leiter,et al.  2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. , 2022, The Canadian journal of cardiology.

[2]  A. Barry,et al.  Decisional Needs and Patient Treatment Preferences for Heart Failure Medications: Scoping Review Protocol , 2022, medRxiv.

[3]  N. Choudhry,et al.  Evidence-Based Prescribing and Polypharmacy for Patients With Heart Failure , 2021, Annals of Internal Medicine.

[4]  R. McKelvie,et al.  CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. , 2021, The Canadian journal of cardiology.

[5]  P. Ponikowski,et al.  Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. , 2021, Journal of cardiac failure.

[6]  G. Fonarow,et al.  2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2021, Journal of the American College of Cardiology.

[7]  Candace D. Speight,et al.  Show Me the Money , 2020, Circulation. Cardiovascular quality and outcomes.

[8]  Candace D. Speight,et al.  Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions , 2020, Circulation. Heart failure.

[9]  Miranda E. Kroehl,et al.  Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study , 2020, Patient preference and adherence.

[10]  L. Allen,et al.  An Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction: The EPIC-HF Trial. , 2020, Circulation.

[11]  Neal W. Dickert,et al.  Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan , 2020, Circulation. Cardiovascular quality and outcomes.

[12]  A. O'Connor,et al.  20th Anniversary Update of the Ottawa Decision Support Framework Part 1: A Systematic Review of the Decisional Needs of People Making Health or Social Decisions , 2020, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  A. O'Connor,et al.  20th Anniversary Update of the Ottawa Decision Support Framework: Part 2 Subanalysis of a Systematic Review of Patient Decision Aids , 2020, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  K. Anstrom,et al.  Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. , 2020, JAMA cardiology.

[15]  A. O'Connor,et al.  20th Anniversary Ottawa Decision Support Framework: Part 3 Overview of Systematic Reviews and Updated Framework , 2020, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  M. DiGiacomo,et al.  Patient preferences for heart failure education and perceptions of patient-provider communication. , 2020, Scandinavian journal of caring sciences.

[17]  G. Fonarow,et al.  Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. , 2019, JAMA cardiology.

[18]  R. Meraz.  Medication Nonadherence or Self-care? Understanding the Medication Decision-Making Process and Experiences of Older Adults With Heart Failure , 2019, The Journal of cardiovascular nursing.

[19]  P. Goyal.  Do We Need Shared Decision Making When Prescribing Guideline-Directed Medical Therapy? , 2019, Journal of cardiac failure.

[20]  P. Hauptman,et al.  Heart Failure, Shared Decision Making, and Social Determinants of Health: An Upstream Perspective. , 2019, JAMA cardiology.

[21]  J. H. Patterson,et al.  Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[22]  Candace D. Speight,et al.  Discussing Out‐of‐Pocket Costs With Patients: Shared Decision Making for Sacubitril‐Valsartan in Heart Failure , 2018, Journal of the American Heart Association.

[23]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[24]  J. McGowan,et al.  PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation , 2018, Annals of Internal Medicine.

[25]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[26]  M. Walsh,et al.  Effectiveness of an Intervention Supporting Shared Decision Making for Destination Therapy Left Ventricular Assist Device , 2018, JAMA internal medicine.

[27]  R. McKelvie,et al.  2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. , 2017, The Canadian journal of cardiology.

[28]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[29]  R. Meraz.  Making medication adherence decisions: Stories from older adults taking medications for congestive heart failure , 2017 .

[30]  H. Bosworth,et al.  Unmet expectations of medications and care providers among patients with heart failure assessed to be poorly adherent: results from the Chronic Heart Failure Intervention to Improve MEdication Adherence (CHIME) study , 2017, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[31]  A. Tonkin,et al.  Attitudes of Patients and Prescribing Clinicians to Polypharmacy and Medication Withdrawal in Heart Failure. , 2016, Journal of cardiac failure.

[32]  I. Higginson,et al.  The gap between policy and practice: a systematic review of patient-centred care interventions in chronic heart failure , 2015, Heart Failure Reviews.

[33]  Adrian F. Hernandez,et al.  Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence (CHIME) Study: A Randomized Intervention in High-Risk Patients , 2015, American heart journal.

[34]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[35]  Adrian F. Hernandez,et al.  The meanings associated with medicines in heart failure patients , 2013, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[36]  A. Mühlbacher,et al.  Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making? , 2013, Applied Health Economics and Health Policy.

[37]  N. Cook,et al.  Decision Making in Advanced Heart Failure A Scientific Statement From the American Heart Association Endorsed by Heart Failure Society of America, American Association of Heart Failure Nurses, and Society for Medical Decision Making , 2022 .

[38]  M. Pfisterer,et al.  End-of-life preferences of elderly patients with chronic heart failure. , 2012, European heart journal.

[39]  C. Dennison,et al.  Patient-, Provider-, and System-Level Barriers to Heart Failure Care , 2009, The Journal of cardiovascular nursing.

[40]  Trudy van der Weijden,et al.  Assessing the Quality of Decision Support Technologies Using the International Patient Decision Aid Standards instrument (IPDASi) , 2009, PloS one.

[41]  Jia-Rong Wu,et al.  Medication adherence in patients who have heart failure: a review of the literature. , 2008, The Nursing clinics of North America.

[42]  J. George,et al.  Predictors of refill non-adherence in patients with heart failure. , 2007, British journal of clinical pharmacology.

[43]  S. Ziebland,et al.  'Can I come off the tablets now?' A qualitative analysis of heart failure patients' understanding of their medication. , 2006, Family practice.

[44]  A. Coats,et al.  A qualitative study of chronic heart failure patients’ understanding of their symptoms and drug therapy , 2002, European journal of heart failure.

[45]  L. Stevenson,et al.  Preferences for quality of life or survival expressed by patients with heart failure. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[46]  T. Rector,et al.  Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. , 1995, Journal of cardiac failure.

[47]  G. Fonarow,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Circulation.

[48]  R. Thomson,et al.  Decision aids for people facing health treatment or screening decisions. , 2003, The Cochrane database of systematic reviews.